🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being hailed as a "huge turning point" in the fight against drug-resistant strains of the pathogen, according to researchers.

A Global Challenge

The sexually transmitted infection are increasing around the world, with figures suggesting more than 82 million instances annually. Especially elevated rates are observed in Africa and countries within the World Health Organization's Western Pacific region, which includes Mongolia and China to New Zealand. Across England, cases have hit a record high, while infection numbers across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of new treatments for gonorrhoea is an critical and opportune development in the context of rising global incidence, the spread of superbugs and the extremely scarce treatment choices at this time.”

Public health authorities are deeply concerned about the rise in drug-resistant strains. The WHO has classified it as a "priority pathogen". Recent surveillance showed that resistance to primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Therapies Receive Approval

One new antibiotic, also known as a brand name, was cleared by the US FDA in recent days for use against gonorrhoea. This infection can lead to serious health problems, including infertility. Scientists believe that targeted use of this new drug will help slow the development of resistance.

Gepotidacin, created by the drugmaker GlaxoSmithKline, was also approved in concurrent days. This drug, which is employed against urinary tract infections, was proven in research to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment stemmed from a unique collaborative effort for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the drug firm Innoviva to see it through.

“This authorization represents a huge turning point in the management of superbug gonorrhoea, which previously has been staying ahead of medical innovation.”

Clinical Trial Results and Worldwide Availability

According to data published in a prominent scientific publication, the new drug successfully treated more than 90% of uncomplicated infections. This places it at an equal footing with the existing first-line therapy, which combines two antibiotics. The study enrolled over 900 volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, the non-profit has the ability to make available and distribute the drug in a wide range of low-income and middle-income countries.

Medical professionals treating patients have expressed positive views. The availability of a single-dose, oral treatment like this is seen as a "game-changer" for public health efforts. This is deemed essential to reduce the burden of the infection for patients and to prevent the spread of extremely resistant gonorrhoea around the world.